Viva Biotech Holdings (HKSE:01873) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01873 Viva Biotech Holdings HKSE:01873
56 GF Score
Price HK$1.18
GF Value HK$0.78
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01873
56GF Score
Viva Biotech Holdings HKSE:01873
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viva Biotech Holdings (HKSE:01873) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of HK$1.18 is trading 51.3% above its estimated GF Value™ of HK$0.78. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:01873:

  • FFO:
  • GF Value™: HK$0.78 vs. price of HK$1.18 (51.3% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01873 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USAVB0:Germany
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
56GF Score

Get the complete analysis for HKSE:01873

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.18
Price
HK$0.78
GF Value